The Food and Drug Administration (FDA) has approved 2 additional vial sizes of Niktimvo ™ (axatilimab-csfr), 9mg/0.18mL and 22mg/0.44mL, in addition to the 50mg/mL size.

French biotech MaaT Pharma says its acute graft-versus-host disease treatment exceeded expectations in a single-arm Phase 3 ...

Graft-Versus-Host disease market Insights. DelveInsight's Graft-Versus-Host Disease Market report offers an in-depth understanding of the epidemiology and ...

Sergio A. Giralt, MD, discusses how he selects patients with chronic graft-vs-host disease (cGVHD) for treatment with ...

Niktimvo marks the first FDA-approved therapy targeting CSF-1R to address inflammation and fibrosis in chronic ...

A YOUNG mum battling a rare form of cancer passed away surrounded by loved ones after suffering complications from treatment.

Incyte and Syndax Pharmaceutical said the Food and Drug Administration approved their graft disease treatment Niktimvo antibody in nine milligram and 22 milligram vial sizes.

14 for the treatment of chronic graft-versus-host disease after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kilograms. Graft-versus ...

CARsgen’s allogeneic CD38 CAR-T therapy administers first dose in an investigator-initiated trial: Shanghai, China Tuesday, January 21, 2025, 18:00 Hrs [IST] CARsgen Therapeutic ...

Top-line data from Maat Pharma SA’s phase III study of MaaT-013, an enema microbiome ecosystem therapy for acute graft-vs.-host disease, hit its primary endpoint. The milestone has prompted the ...

When Anne Maldzinski underwent a blood stem-cell transplant to cure her cancer, the procedure triggered a life-threatening ...